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Abstract
Elite suppressors (ES) are a rare subset of HIV-1–infected individuals who are able to maintain HIV-1 viral loads below the
limit of detection by ultra-sensitive clinical assays in the absence of antiretroviral therapy. Mechanism(s) responsible for this
elite control are poorly understood but likely involve both host and viral factors. This study assesses ES plasma-derived
envelope glycoprotein (env) fitness as a function of entry efficiency as a possible contributor to viral suppression. Fitness of
virus entry was first evaluated using a novel inducible cell line with controlled surface expression levels of CD4 (receptor)
and CCR5 (co-receptor). In the context of physiologic CCR5 and CD4 surface densities, ES envs exhibited significantly
decreased entry efficiency relative to chronically infected viremic progressors. ES envs also demonstrated slow entry kinetics
indicating the presence of virus with reduced entry fitness. Overall, ES env clones were less efficient at mediating entry than
chronic progressor envs. Interestingly, acute infection envs exhibited an intermediate phenotypic pattern not distinctly
different from ES or chronic progressor envs. These results imply that lower env fitness may be established early and may
directly contribute to viral suppression in ES individuals.
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Introduction
A minor subset of HIV-1–infected individuals maintains stable
CD4
+ T cell counts in the absence of antiretroviral therapy. A
small proportion of these long-term nonprogressors (LTNPs),
termed elite suppressors (ES), control plasma viral loads to ,50
copies/ml [1]. Mechanism(s) responsible for this elite control are
poorly understood but likely involve host and viral factors. Studies
have explored the contributions of the innate and adaptive
immune responses, host genetic polymorphisms, and viral
dynamics (reviewed in [2]). For example, the major histocompat-
ibility complex class (MHC) I group B alleles HLA-B27, -B51, and
–B57 have been strongly associated with slower rates of HIV-1-
associated disease progression [3–6]. Although these HLA-B
alleles are overrepresented in ES and LTNPs, they are only
expressed in a subset of these individuals indicating that the
presence of these alleles is not necessary to suppress viremia and
that other factors are likely involved [4,7].
Although much previous work on ES has focused on host
factors, less is known about viral fitness in these individuals. The
impact of viral attenuation on disease progression was first
described in a cohort of LTNPs infected by a common donor
with virus containing a deletion in the nef gene [8,9]. Investigation
of other LTNP cohorts has shown both the presence [10,11] and
absence [12,13] of defective nef genes. In other cohorts, the
presence of viruses with reduced replication capacity has been
associated with slower disease progression [14–19]. This viral
attenuation could be the result of divergent evolution as a result of
direct selective pressure by the host immune response [16–19].
However, recent work has shown that replication-competent
viruses can be recovered from ES individuals indicating that ES
harbor functional virus [20]. Furthermore, large scale sequencing
of ES viruses yielded no identifiable common genetic defects [21].
Investigating the relative fitness of viral quasispecies in ES will help
determine whether viral fitness is influencing disease outcome in
these individuals.
PLoS Pathogens | www.plospathogens.org 1 April 2009 | Volume 5 | Issue 4 | e1000377Low HIV-1 genetic diversity in ES may be indicative of the
presence of lower fitness variants [22]. Sequence analysis of
functional envelope glycoprotein ES clones showed significantly
decreased env diversity compared to individuals with chronic
viremia suggesting that viruses in these patients experience minimal
viral replication and diversification [23]. Lack of env diversification
suggests that ES envs may be closely related in genotype and
phenotype to the founder virus establishing infection.
In this study we have performed rigorous phenotypic analysis on
subtype B env clones from ES plasma virus to determine whether
env fitness may be contributing to viral suppression in ES. A novel
cell line was utilized to show that ES env clones exhibit low CD4
receptor and CCR5 co-receptor usage and slow fusion kinetics
compared to chronic infection envs. Analysis of control viruses
indicated that these characteristics directly correlated to reduced
replication capacity in vitro. Acute infections envs were intermediate
in their entry efficiency and not significantly different from either
chronic or ES envs. This study provides the first direct evidence
that decreased env function is a property of ES and that this may
contribute to viral suppression.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Johns Hopkins School of Medicine
and Rockefeller University hospitals. All patients provided written
informed consent for the collection of samples and subsequent
analysis.
Patient profiles
The elite suppressor and chronic progressor patients have been
previously described [23] (Table 1). Patients identified with acute/
early HIV-1 infection have been previously described [24]. The
estimated duration of infection was calculated 2 weeks prior to the
onset of acute retroviral illness unless the patient could identify a
precise high risk event. Table 1 contains relevant enrollment data
for all acute/early infection patients. Elite suppressors were
defined as individuals who maintained viral load to below 50
copies of RNA/ml plasma in the absence of retroviral therapy yet
were Western blot positive for infection. Informed consent was
obtained prior to phlebotomy. The protocol for ES/CP or acute/
early infection was approved by an institutional review board of
the Johns Hopkins University School of Medicine and the Aaron
Diamond AIDS Research Center, respectively.
Generation of pseudotype virus and infection of
Affinofile cells
Envelope expression vectors were generated as previously
described [23]. Envelope pseudotypes were generated by cotransfec-
tion of 293T cells with the 1 mg of the luciferase-encoding
pseudotyping vector pNLLuc.AM and 1 mgo fe n v e l o p ee x p r e s s i o n
vector. Cells were washed after 24 h, and pseudoviruses were
collected after a subsequent 48 h. Relative particle numbers were
determined by limiting dilution reverse transcriptase assay. Viruses
were characterized as exclusively CCR5-utilizing by comparison of
infectivity of U87-CD4/CCR5 and U87-CD4/CXCR4 cells, as
previously described [25]. Affinofile cells were generated by selection
of 4 vector stable cells (Johnston et al., submitted). CCR5 expression is
controlled by a two vector ecdysone-inducible promoter. pVgRXR
encodes the VgEcR fusion protein under control of the CMV
promoter, and the RXR open reading frame under control of the
RSV 59 long terminal repeat. pIND-CCR5 encodes CCR5 under
control of the minimal heat shock promoter with inducible control
provided by five repeats of the glucocorticoid receptor DNA binding
domains (56E/GRE). Addition of the ecdysone derivative ponaster-
one A (the inducer) results in recruitment of a transcriptional
coactivator to the 56E/GRE element and activation of transcription
of the CCR5 ORF. CD4 expression is inducibly regulated by the
TREx expression system (Invitrogen). Cells contain pcDNA5-TO-
CD4 and transcription of the CD4 ORF is controlled by the addition
ofthe tetracycline analog minocycline.Singlecellcloneswereisolated
to generate cell populations with consistent levels of induction upon
stimulation of CD4 and CCR5 expression.
Affinofile cells were plated at a density of 10,000 cells per well in
a 96-well plate and allowed to adhere for 48 hours. Cells were
induced in a matrix pattern to express CD4 and CCR5.
Minocycline was added to cells in 2-fold dilutions over 6 separate
dilutions (5 ng/ml–0 ng/ml) to induce CD4 expression. Ponaster-
one A was added in 2-fold dilutions over 6 separate dilutions from
a final concentration of 4 mMt o0 mM to induce CCR5
expression. This matrix results in 36 unique CD4 and CCR5
induction surface concentrations. Each drug concentration was
induced in triplicate. Cells were induced for 24 hours prior to
infection. Cells were then exposed to pseudovirus for 48 h, washed
with PBS, and lysed with Glo lysis buffer (Promega, Inc.). Maximal
infection was considered luciferase activity generated by infection
at the highest CD4 and highest CCR5 concentration. To control
for effects caused directly by minocycline and/or ponasterone A
on viral infectivity, U87-CD4/CCR5 cells were treated with a
similar matrix of both drugs. CCR5 and CD4 expression levels
were unchanged by flow cytometry, and no changes in infectivity
of Yu-2 and SF162 envelope pseudoviruses were noted, thus
variation in infectivity was assumed to be due to variations in
receptor expression levels (Johnston et al, submitted).
Kinetic fusion and reverse transcription assays
For the kinetic fusion assay, HIV-1 pseudoviruses bearing either
ES or chronic envelopes were spinonculated onto U87-CD4/
CCR5 cells. 2.5610
6 cells were spin-infected with pseudovirus-
containing supernatant for 90 min at 1,2006ga t4 uC. The cells
were washed twice with cold phosphate buffered saline (PBS) to
Author Summary
The majority of HIV-1–infected individuals experience high
plasma viral loads and CD4
+ T cells loss in the absence of
antiretroviral therapy. However, a very rare and important
subset of individuals termed elite suppressors is able to
maintain HIV-1 plasma viral loads below the limit of viral
detection in the absence of treatment. The reasons behind
this ability to control the virus are poorly understood, but
they likely involve both an effective host immune response
against HIV-1 and factors related to the virus itself. Here,
we analyze the function of the HIV-1 coat protein or
envelope glycoprotein from a group of elite suppressors.
HIV-1 envelope mediates entry into the host cell via
interaction with the cellular receptors CD4 and CCR5.
Envelopes from elite controllers interacted with these
receptors inefficiently compared to those from individuals
with detectable viral loads. These inefficient interactions
by elite suppressor envelopes led to slow rates of entry
into host cells. Envelopes from acutely infected individuals
were not significantly different from elite suppressors or
chronically infected individuals. These findings suggest
that the decreased envelope efficiency may contribute to
viral control in elite suppressors.
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and split into 96-well plates (50 ml/well). Virus-cell mixes were
synchronized for entry by addition of 130 mlo f3 7 uC medium, and
then ENF at 10 mM was added to each well in 20 ml of medium at
fixed-time intervals after addition of warm medium, which is
defined as tim=0 for synchronization of viral replication. Cells
were incubated for 48 h and then treated with lysis buffer and
luciferase activity was determined. For the kinetic fusion assay
6 hours was used as 100% or maximal luciferase activity. For the
reverse transcription assay, Affinofile cells were induced with
5 ng/ml minocycline 24 hours prior to infection. ES or chronic
pseudoviruses were synchronously added to cells. Efavirenz (EFV)
was added at a concentration of 1 mM to each well at fixed time
intervals after the addition of virus. For reverse transcription assay,
12 hours was used as 100% or maximal luciferase activity.
Entry inhibitor susceptibility
Affinofile cells were induced 24 hours prior to infection with
5 ng/ml minocycline. Cells were incubated with serial 10-fold
dilutions of either chemokine (CCL5 [50 nM to 0.1 nM]) or drug
Table 1. Patient characteristics of elite suppressors, chronic progressors, and acutely infected individuals.
Patient
Year of
diagnosis
Sampling
date
Duration of
infection
a
Plasma viral load
(RNA copies/ml)
CD4 count
(cells/ml)
Elite Suppressors
ES2 1986 5/04 18 years ,50 383
ES3 1991 3/04 13 years ,50 677
ES4 1996 8/04 8 years ,50 837
ES7 1994 1/05 11 years ,50 1,125
ES8 2003 6/04, 9/04 1 year ,50 458
ES9 1999 3/04, 8/04 5 years ,50 800
ES10 2002 3/04 2 years ,50 900
Chronic Progressors
C61 1999 9/04 5 years 19,100 1,261
C62 1998 9/04 6 years 33,300 481
C93 2001 3/05 4 years 47,270 402
C94 1999 2/05 6 years 22,898 351
C96 2001 3/05 4 years 12,500 400
C98 2004 3/05 1 year 17,838 426
C109 2002 5/05 3 years 61,000 222
Acute Infection
502 – – 19 days 31,622,777 306
503 – – 17 days 588,844 531
504 – – 32 days 2,691,535 152
506 – – 43 days 467,735 341
508 – – 26 days 389,045 266
510 – – 16 days 1,584,893 581
512 – – 25 days 3,388,442 745
514 – – 26 days 676,083 291
516 – – 51 days 295,121 371
517 – – 38 days 87,096 588
518 – – 15 days 21,379,621 226
519 – – 22 days 1,819,701 322
520 – – 40 days 257,040 512
522 – – 21 days 3,235,937 583
523 – – 28 days 173,780 273
526 – – 26 days 100,000 205
527 – – 21 days 134,896 538
528 – – 16 days 12,022,644 438
529 – – 19 days 28,840,315 537
530 – – 30 days 6,456,542 469
aTime of infection expressed in approximate years for ES and CP patients from diagnosis to sampling. Time of infection for acute infection samples estimated by 14 days
after the onset of acute seroconversion symptoms or identification of high risk transmission event, and sampling was conducted ,4 weeks post-presentation and
initiation of HAART.
doi:10.1371/journal.ppat.1000377.t001
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1 h prior to the addition of virus. Cells were incubated for 48 h,
washed with PBS, lysed, and luciferase activity determined. Plots
of luciferase activity versus drug concentration were used to
determine IC50 values for each pseudovirus. Luciferase activity
without drug was used as maximal or 100% infection value.
Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated from
heparin-treated venous whole blood from HIV–seronegative
donors by Ficoll-paque density gradient centrifugation (GE
Healthcare, Piscataway, NJ). Isolated PBMCs were washed twice
in wash buffer [phosphate-buffered saline (PBS) supplemented
with 2% fetal bovine serum (FBS), 0.1% glucose, 12 mM HEPES,
and penicillin (100 U/m) and streptomycin (100 mg/ml)] and
activated in RPMI 1640 (Mediatech, Inc., Manassas, VA)
supplemented with 10% FBS, penicillin/streptomycin, and
2 mg/ml phytohemmaglutinin (PHA, Sigma-Aldrich, St. Louis,
MO) and 100 U/ml interleukin 2 (IL-2, Invitrogen, Carlsbad, CA)
for 3 days at 37uC and 5% CO2. Total PBMCs were subsequently
maintained in RPMI 1640 supplemented with 10% FBS, pen/
strep, and 100 U/ml IL-2. For flow cytometry experiments, a total
of 10u PBMCs were collected 4 days post-stimulation by
centrifugation at 2500 rpm610 minutes and washed once in
FACS staining buffer (PBS with 2% FBS, 0.5% bovine serum
albumin, and 0.02 sodium azide). The cells were incubated in
either an anti-CD4 antibody [Fluorescein isothiocyanate(FITC)-
conjugated anti-CD4, BD Biosciences Pharmingen, San Jose, CA]
or FITC-conjugated IgG1 isotype control (BD Biosciences
Pharmingen), or an anti-CCR5 antibody [Phycoerythrin(PE)-
conjugated anti-CCR5 clone CTC5, R&D Systems, Minneapolis,
MN] or PE-conjugated IgG2B isotype control (R&D Systems). All
antibodies were incubated at a final concentration of 12.8 mg/ml
for 30 minutes at room temperature in FACS staining buffer.
Stained PBMCs were washed again in FACS staining buffer and
samples were analyzed on a FACSCalibur flow cytometer (Becton
Dickinson, Franklin Lakes, NJ) with Cellquest software. For
assessment of Affinofile cell receptor expression levels relative to
PBMCs, 5.0610
5 cells were added to a 6-well plate and allowed to
adhere for 48 hours in Dulbecco’s Modified Eagle’s Medium
(DMEM, Mediatech, Inc.) supplemented with 10% FBS, pen/
strep, and 50 mg/ml blasticidin (Sigma). Cells were stimulated with
20 ng/ml minocycline (Sigma) for 24 hours and subsequently
recovered from plates with 3 mM EDTA in PBS. Cells were
washed, stained, and analyzed by flow cytometry as reported
above for PBMCs. Flow cytometry of PBMCs and Affinofile cells
was performed in the same experiment. Results were analyzed by
Flow-Jo software and receptor expression levels reported as events
relative to mean fluorescence intensity.
Pseudovirus incorporation of envelope glycoproteins
Envelope-pseudotyped viruses prepared withES or CP envelopes
by transfection of 293T cells were quantified by limiting dilution
reverse transcriptase activity. Equivalent virion numbers were
pelleted by centrifugation at 38,0006g for 2 hours at 4uC.
Supernatant was removed and virion pellets were lysed in SDS
lysis buffer [40 mM Tris-HCl (pH 6.8), 10% glycerol, 10% ß-
mercaptoethanol, 1% SDS]. Virus lysates were separated on SDS-
10% polyacrylamide gels and transferred to nitrocellulose. Mem-
branes were blocked with gelatin and proteins were detected either
with a mouse monoclonal anti-gp120 antibody that recognizes a
conserved C2 region linear epitope (B13, courtesy of Dr. Bruce
Chesebro, NIAID ) or HIV-Ig (courtesy AIDS Research and
Reference Reagent Program). Primary antibodies were detected
with horseradish peroxidase-conjugated goat-anti-mouse or goat-
anti-human secondary antibodies, respectively (Pierce Biotechnol-
ogy, Rockford, IL), revealed with the ECL Plus Western Detection
kit (Pierce Biotechnology) and exposed to X-ray film.
Statistical analysis
Data were analyzed by the UCLA Statistical/Biomathematical
Consulting Clinic using repeated measures ANOVA, simulta-
neously taking into account effects due to disease group (ES vs CP),
CD4 level, and CCR5 level. Within each group, the intrapatient
variability in relative infection was small and did not differ
significantly between the ES and CP groups. Therefore, results are
reported with interpatient variance. For evaluation of surface plots
between groups ES and CP, P values are given using the average
of clones for a given patient as a single value or using each
individual clone as a single value. For groups of 3 or more (ES, CP,
and acute) we evaluated independent means by One-way ANOVA
using the Kruskal-Wallis test and Dunns post-test for data that did
not pass a normalcy test. For drug sensitivity and kinetic analysis
statistics were performed using each individual clone as a single
value. We considered a P value of ,0.05 as statistically significant.
Results
Measuring HIV-1 entry efficiency and fitness by varying
CD4 and CCR5 cell surface concentrations
The ability of HIV-1 to infect a cell is largely influenced by
surface expression of CD4 and CCR5 [26–32]. This study
evaluates a previously described cohort of 38 independent full-
length plasma env clones derived from 7 ES individuals [23]. The
env clones from this cohort expressed similar levels of protein by
Western blot (Figure S1) and readily infected the indicator cell line
TZM-bl demonstrating their functionality [23]. As described
below, observed differences in entry efficiency could not be
explained by any minor variations in Env levels on the virus.
As with most cell lines, TZM-bls express CD4 at levels
comparable to primary activated CD4
+ T cells (approximately
65,000–100,000 molecules/cell), however CCR5 expression is
significantly higher than on primary T lymphoctyes (approxi-
mately 500 to 7000 molecules/cell) [26,33–37]. CCR5 expression
also varies widely from patient to patient not only in absolute
number of cells expressing CCR5, but also in CCR5 density/cell
[26,27,33–35]. This study utilizes the Affinofile system, a novel cell
line with independent dual-inducible surface expression of CD4
and CCR5 (Figure 1, Figure S1) (Johnston et al., submitted). The
ability to modulate receptor and co-receptor expression on the
Affinofile cells provides a more physiologic measure of HIV-1
entry efficiency. Since the ability of HIV-1 to infect a cell is largely
influenced by cell surface levels of CD4 and CCR5, it is important
to consider expression levels when evaluating infectivity [26–32].
Receptor usage as measured by the Affinofile system was
validated as a surrogate marker of entry fitness. Yu-2 and a V3
crown mutant of Yu-2 [Yu-2(Y318R)] known to affect CCR5
usage were evaluated for infectivity using Affinofile cells induced at
each pairwise combination of [Minocycline] and [Ponasterone A]
(42 unique combinations) (Figure S1). Three-dimensional surface
plots were generated from luciferase activity expressed as a
function of virus infectivity at each combination of CCR5 and
CD4, which was confirmed by flow cytometry (Figure 1A). CD4
and CCR5 surface levels at each drug combination are given as an
average level calculated from a pool of cells expressing a range of
CD4 and CCR5 molecules (Figure S4). Reduced infectivity of the
Yu-2(Y318R) variant over the wild type was observed over a range
of CCR5 and CD4 (Figure 1A). This decreased ability of
Lower Elite Suppressor HIV-1 env Fitness
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with a 90% reduction in replicative fitness measured by
competitive replication assays in peripheral blood mononuclear
cells (PBMCs) (Figure 1B, p,0.01, unpaired student’s t-test). The
direct relationship between entry efficiency using the Affinofile
system and replicative fitness in human PBMCs has been validated
for multiple primary HIV-1 isolates. Generally, viruses of
increased replicative fitness display increased infectivity of cells
expressing low CCR5, CD4, or both CCR5 and CD4 in the
Affinofile system (Johnston et al, submitted).
To assess relative infectivity of chronic and ES env clones,
pseudotyped viruses carrying a non-LTR driven luciferase were
generated for each clone. Pseudotyped viruses generated from 38
independent plasma virus env glycoprotein clones from 7 ES and
32 independent plasma virus clones from 7 chronic progressors
(CP) were evaluated for infectivity at each pairwise drug
Figure 1. Affinofile cells allow for the analysis of both CD4 and CCR5 usage and are a surrogate marker of fitness. (A) Affinofile cells
were infected with Luciferase-encoding envelope psudotyped viruses bearing the envelope of the neurotropic lab strain Yu-2 or a V3-crown mutant
[Yu-2(Y318R)] with reduced CCR5 usage. Surface plots were constructed using infectivity data derived from luciferase activity. Percent infection (y-
axis) was derived from the luciferase activity at each receptor expression combination divided by the luciferase activity at maximal CD4/CCR5
expression levels. The x-axis depicts approximate CD4 expression level described as approximate molecules CD4/cell as assessed by quantitative flow
cytometry (top 2 panels), and the z-axis depicts approximate CCR5 expression levels (bottow 2 panels). (B) Relative replicative fitness of full length
HIV-1 viruses in multiple replication cycle in primary PHA/IL-2–activated peripheral blood mononuclear cells. The replicative fitness of full length Yu-2
and Yu-2(Y318R) was determined by pairwise infection and quantification of relative outgrowth. The y-axis represents percent replicative fitness of
Yu-2(Y318R) relative to Yu-2.
doi:10.1371/journal.ppat.1000377.g001
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(Figure S2 and Figure S3). The percent infection defines the
infection at each surface CCR5/CD4 level relative to a 100%
infection at the highest CD4 and CCR5 surface density. This
method permits the direct comparison of CD4 and CCR5 usage
by each env clone and provides a rapid and efficient way to
measure viral env replicative fitness.
ES are less efficient than CP env clones in utilizing both
CCR5 and CD4 for entry
Relative infectivity of 38 independent ES env clones and 32
independent CP env clones was ascertained at multiple combina-
tions of CCR5 and CD4 density (Figure 2A–2F and Figure 3A–
3F). Values for each of the env clones tested are shown as well as for
Yu-2 and SF162. Varying CD4 levels with constant CCR5
(Figure 2A–2F) or varying CCR5 levels with constant CD4
(Figure 3A–3F) consistently demonstrated that ES env clones
supported lower levels of infection than the CP clones.
At the highest CD4 and lowest CCR5 expression level, ES
clones averaged 36.7% while CP clones were reliably higher
averaging 53.3% (Figure 2A–2C). Infectivity differences were
significant for each CD4 concentration (P values ranged from 0.01
to ,0.0001, repeated measures ANOVA) at a fixed high or low
CCR5 level regardless if individual env clones were evaluated
(Figure 2C and 2F) or if the env clones were averaged for a given
individual and compared as patient averages (Figure 2B and 2E).
Additionally, consistent with previous data, the neurotropic envs
Figure 2. ES clones show reduced entry efficiency at fixed CCR5 surface concentrations. (A–C,D–F) Affinofile cells were induced to express
approximately 1274 CCR5 molecules/cell (A–C) or approximately 21,073 CCR5 molecules/cell (D–F) and CD4 molecules ranging from approximately
1,800 to 125,000 molecules/cell prior to infection. Induced Affinofile cells were infected with equivalent amounts of pseudotyped viruses. Relative
infection of all CP (black) and ES (red) clones are shown with SF162 and YU-2 included as positive controls (blue). Relative infection is expressed as a
proportion of maximal infection at the highest CD4 (approximately 125,000 molecules/cell) and CCR5 (approximately 21,073 molecules/cell) level.
(B,E) Infectivity of clones from individuals were averaged and plotted as a single line for chronic and ES individuals. P values are given for patient
averages. (n=7) (C,F) Average of all individual chronic or elite clones at minimal (C) and maximal (F) CCR5 concentrations with CD4 concentrations
ranging from approximately 1,800 to 125,000 molecules/cell. Affinofile cells were induced as described above for (A,B). P values as calculated by
unpaired student’s t test are shown above each CD4 expression condition. P values are represented as follows: P,0.05 (*), P,0.01 (**), P,0.001 (***),
P,0.0001 (****). 95% confidence intervals are shown for chronic (grey) and ES (pink).
doi:10.1371/journal.ppat.1000377.g002
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levels of CD4 while the primary isolates could not (Figure 3A–3F)
[38]. Taken together, these results reveal that ES clones
inefficiently infect cells expressing low CCR5 in the presence of
threshold or higher levels of CD4 compared to CP clones.
Additionally, the discrepancy in infectivity between ES and
chronic clones at fixed, high CCR5 levels indicates that ES clones
also require higher levels of CD4 to achieve similar infection as
chronic clones.
To further evaluate CCR5 usage independent of CD4
expression, infection was determined at minimal and maximal
CD4 levels as CCR5 expression was varied. At each concentration
of CCR5 below maximal examined, ES clones infected signifi-
cantly less efficiently than chronic clones (Figure 3D–3F).
Therefore, even in the presence of optimal CD4 concentrations,
ES clones inefficiently utilize CCR5 for entry.
ES env clones do not differ significantly from acute
infection env clones in CD4 and CCR5 utilization
Differences in receptor and co-receptor utilization of ES and
chronic progressor envs were most significant when infection was
performed in the context of (1) low CCR5 and varying CD4 levels
or (2) low CD4 and varying CCR5 levels. Thus, these conditions
were repeated to examine entry efficiency of 23 pseudotyped env
plasma clones from 20 acutely infected individuals (Figure 4A and
4B). At low CCR5 expression, acute envs averaged an intermediate
pattern of infectivity compared to ES and chronic envs, but these
differences were not significant (Figure 4A). Similar results were
obtained when infections were performed at minimal surface CD4
levels (Figure 4B). Consistent with previous reports using similar
systems, these results indicate that acute envs show a broad pattern
of infectivity which is not significantly different from chronic or ES
envs [39].
Figure 3. ES clones show reduced entry efficiency at fixed CD4 surface concentrations. (A–C,D–F) Affinofile cells were induced to express
threshold (approximately 2,500) CD4 molecules/cell (A–C) or maximal (approximately 125,000) CD4 molecules/cell (D–F) and CCR5 molecules ranging
from approximately 1274 to 21,073 molecules/cell prior to infection. Infection is performed as described in Figure 2. (B,E) Infectivity of clones from
individuals were averaged and plotted as a single line for chronic and ES individuals. P values are given for patient averages. (n=7) (C,F) Average of all
individual chronic or elite env clones at threshold (C) and maximal (F) CD4 concentrations with CCR5 concentrations ranging from approximately
1274 to 21,073 molecules/cell. P values are represented as follows: P,.05 (*), P,.01 (**), P,.001 (***), P,.0001 (***). 95% confidence intervals are
shown for chronic (grey) and ES (pink).
doi:10.1371/journal.ppat.1000377.g003
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Previous studies suggest that major differences in entry
efficiency may impact on susceptibility to various entry inhibitors
[25,40–42]. Thus ES, CP, and acute clones were tested for their
susceptibility to the natural CCR5 ligand CCL5 (RANTES), the
small molecule CCR5 antagonist TAK-779, and the fusion
inhibitor enfuvirtide (ENF) in Affinofile cells induced to express
CD4 and CCR5 to levels that closely mimic primary CD4
+ T cells
(approximately 125,000 molecules CD4/cell and 1274 molecules
CCR5/cell) (Figure S4). Susceptibility to CCL5 did not differ
significantly between chronic and ES env clones (Figure 5A).
Interestingly, acute clone IC50 values ranged from 0.05 to 50 nM
(1,000-fold) with an average of 8.25 nM. The range of IC50 values
for acute clones was much larger relative to ES clones whose
values ranged from 0.4 to 10 nM (25-fold), with an average of
3.05 nM. Although similar trends were observed with the small
molecule CCR5 antagonist TAK-779, clones were not signifi-
cantly different with average IC50 values of 48.8 nM for acute,
21.0 nM for chronic, and 14.7 nM for ES (Figure 5B). These
results show that ES, CP, and acute envs have no remarkable
differential susceptibility to CCL5 or TAK-779 however the broad
range of IC50 values for acute envs highlights the variability in env
phenotypes associated with acute infection.
Finally, susceptibility of clones to ENF was evaluated (Figure 5C).
IC50 values for acute clones again showed a broad range from 0.10
to 623 nM (.5000 foldrange) with an average of 58.13 nM. Again,
ES (33-fold range) clones exhibited a significantly narrower range of
IC50 values compared to acute clones. The average IC50 value for
acute envs was significantly greater than for ES (P,0.05, ANOVA,
Kruskal-Wallis test). Overall, ES clones showed trends towards
increased susceptibility to entry inhibitors consistent with decreased
entry efficiency. These susceptibility profiles suggest that ES clones
have a high degree of phenotypic similarity indicated by the narrow
range of susceptibility to entry inhibitors. Conversely, chronic and
especially acute envs showed broad ranges of susceptibility indicative
of their diverse entry phenotypes.
Figure 4. Acute env clones show no significant receptor or co-receptor utilization difference from chronic or elite envs. (A) Affinofile
cells were induced to express minimal CCR5 (approximately 1274 molecules/cell) and CD4 molecules ranging from approximately 1,800 to 125,000
molecules/cell or (B) threshold (approximately 2,500) CD4 molecules/cell and CCR5 molecules ranging from approximately 1,274 to 21,073 molecules/
cell prior to infection. Induced Affinofile cells were infected with equivalent amounts of pseudotyped viruses. Average of all acute (green), chronic
(black), and elite (red) clones are shown. 95% confidence intervals are given for acute (light green), chronic (grey) and ES (pink).
doi:10.1371/journal.ppat.1000377.g004
Figure 5. ES, CP, and acute clones show no differential susceptibility to CCL5, TAK-779, or ENF. (A–C) ES, acute, and chronic clones were
used to infect Affinofile cells induced to express approximately 125,000 molecules CD4 and approximately 1,274 molecules CCR5/cell. (A) CCL5 was
added in concentrations ranging from 0.1–50 nM, incubated for 1 h, and infected. Plots represent percent replication relative to no drug. 50 percent
inhibitory concentrations of drug (IC50 values) were computed from the curves and plotted for acute, chronic, ES, and Yu-2 or SF162 envelopes. (B)
TAK-779 was added to the induced Affinofile cells at concentrations ranging from 0.1 nM–1 mM. Plots were used to determine IC50 values for each
envelope. (C) Enfuvirtide was added to cells at concentrations ranging from 0.1 nM–1 mM.
doi:10.1371/journal.ppat.1000377.g005
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exhibited by ES–derived env clones
Infection data of cells expressing sub-maximal concentrations of
CD4 and CCR5 indicates that ES-derived env clones require
higher levels of receptor and co-receptor for efficient entry. This
requirement for higher receptor levels could suggest that these envs
also exhibit differences in the rates of HIV-1 entry into host cells
[42,43].
To assess host cell entry kinetics, U87-CD4/CCR5 cells were
first spinoculated with virus at a temperature non-permissive for
viral fusion with the host cell. Enfuviritide (ENF) was added once
to each well at a concentration of 10 mM at various times after the
cells were shifted to temperatures permissive for viral fusion
(Figure 6A). Viruses that have completed the final step in HIV-1
entry (six helix bundle formation) are ENF insensitive and will
continue the viral replication cycle regardless of the addition of
ENF. Thus, this assay permits determination of the entry kinetics
of each env clone.
Fusion kinetics were measured for each ES, CP, and acute
clone. ES clones fused with an average T1/2 of 92.1 minutes while
acute clones averaged a T1/2 of 67.5 minutes and chronic clones a
T1/2 of 58.3 minutes (Figure 6B). This delay in ES fusion kinetics
was significant when compared with acute and CP clones
(P,.0001 and P,.0001 respectively, One-way ANOVA). There-
fore, even in the presence of saturating levels of CD4 and CCR5,
ES clones do not complete entry processes as efficiently and
exhibit slower kinetics than both CP and acute env clones.
This delay in entry kinetics was maintained during subsequent
steps of the replication cycle as indicated by a kinetic reverse
transcription assay. For these analyses, Efavirenz (a non-nucleoside
reverse transcriptase inhibitor) was added at various times post-
infection to arrest infection events which have not completed
reverse transcription. As expected, ES derived env clones
completed reverse transcription slower (mean T1/2 of 8.89 hours)
than acute and CP clones [mean T1/2 values of 7.74 (P,.0001)
and 7.95 (P,.0001) respectively with One-way ANOVA]
(Figure 6C). Due to the isogenic background of the pseudotyping
virus these results suggest that delays in reverse transcription are
the result of delays in entry processes. ES env clones exhibit a
kinetic lag in entry processes which are maintained during
downstream events in the viral life cycle.
Discussion
This study represents an evaluation of intrinsic phenotypic
characteristics of full-length functional subtype B env quasispecies
derived from ES plasma. Envelope glycoproteins from ES clearly
exhibited reduced capacity to support HIV-1 entry into host cells
compared to CP envs. Given the wide range in entry efficiencies
observed with envs derived from acute infections it is possible that
relatively lower fitness env variants are selected early in infection in
ES. The impact of this observed entry deficiency with ES clones is
still not fully understood but decreased replicative fitness and lack
of diversification in ES viruses suggests these individuals may have
contracted a less fit HIV-1 variant or these low fitness variants are
selected for early in infection[7,44,45].
To date, phenotypic studies of ES viruses have been difficult to
perform due to the low amount of virus in these individuals.
Analysis of minor differences in env function has been confounded
by the use of cell lines expressing non-physiologic amounts of co-
receptor (CCR5). Given the high degree of variability in
expression of CCR5 among patients it is important to evaluate
env function over a wide range of CCR5 levels [26,27,34,35].
Detailed analyses of env function in the presence of physiologic
levels of CD4 and CCR5 was possible in this study through the use
of the novel Affinofile system. Although ES and chronic
individuals each harbored quasispecies with different receptor
utilization phenotypes, ES clones from each individual showed an
average decreased entry efficiency compared to chronic clones
over almost all CD4 and CCR5 expression levels. These
differences between chronic and ES clones were most dramatic
at low CCR5 surface levels. Thus, this low fitness phenotype could
be further accentuated in vivo in an individual expressing low
CCR5 levels or possibly higher levels of CCR5 ligands which have
been associated with viral control [46–48].
Several reports have suggested a correlation between suscepti-
bility to entry inhibitors and relative env fitness [25,40]. ES, CP, and
acute clones exhibited a diverse range of IC50 values consistent with
previous data [40,41,43,49,50]. However, acute clones showed
consistentlythemostvariationinsusceptibilityindicatingthediverse
phenotypes associated with early infection [40,43,49]. Conversely,
the low range of IC50 values for ES clones underscores their
phenotypic homogeneity. Due to reported differences between
primary cells and cell lines entry inhibitor susceptibility assays were
performed in the Affinofile cells induced to express CD4 levels and
CCR5 levels that closely mimic primary CD4
+ T cells (approxi-
mately 125,000 molecules CD4/cell and approximately 1274
molecules CCR5/cell) [51]. Additionally, it would be expected that
variations in CD4 utilization would result in variations in
susceptibility to soluble CD4 (sCD4) [52]. However, consistent
with previous reports showing the relative resistance of primary
isolate viruses to sCD4 [53], meaningful inhibition of ES, CP, and
acute infection envelopes was not observed at maximal achievable
concentrations of sCD4 (25 mg/ml).
Previous studies have also highlighted an association between
receptor utilization profiles and susceptibility to neutralizing
antibodies. It is possible that ES envs display altered susceptibility
to broadly neutralizing antibodies given their observed entry
phenotype. Previous studies suggest that antibody binding and
neutralization have a kinetic component [54]. It may potentially be
generalized that slow fusing viruses, independent of the mechanism,
may be more susceptible to neutralizing antibodies that act with a
kinetic dependence.However, ithasbeen shownthat ESindividuals
generate low titers of neutralizing antibodies against autologous
virus and thus the role of neutralizing antibodies in maintenance of
low level viremia in ES is nominal [23].
The host entry process is thought to be a rate limiting step in
HIV-1 replication. It was thus important to determine if poor
entry efficiency by ES clones leads to a reduced rate of entry
kinetics. ES env clones were found to fuse on average over 1.5 times
slower than chronic or acute clones in the presence of saturating
levels of both CD4 and CCR5. As result of poor entry efficiency,
this kinetic delay was maintained during subsequent steps of the
retroviral lifecycle. Compounded effects of inefficient CD4 and
CCR5 usage by ES clones likely contributes to kinetic delays in
entry processes and thus overall decreased replicative fitness. The
delayed entry kinetics may be even more important in vivo if there
is a limited time frame over which entry can occur due to
competing inhibitory processes such as the binding of neutralizing
antibodies or the presence of CCR5 ligands.
Despite genotypic differences in both the virus and the ES host,
viral quasispecies in different ES individuals are remarkably
similar phenotypically. This implies that poor envelope function is
a common feature in ES individuals. This result is in sharp
contrast to data from acute infection envs where clones exhibited
much phenotypic diversity. Potentially, HIV-1 infection in ES may
be established by lower fitness env(s) which are present in a subset
of acutely infected individuals. Alternatively, HIV-1 infection in
Lower Elite Suppressor HIV-1 env Fitness
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pressure from the immune results in the outgrowth of lower fitness
escape variants. At present, no data exists on the natural history of
acute infection of ES. It remains unclear whether these individuals
experience typical high level viremia that is subsequently reduced
to an undetectable setpoint or control their viral load from the
onset of infection. It would be of great interest to be able to address
this significant gap in our understanding of viral dynamics in elite
Figure 6. ES clones show slower fusion and reverse transcription kinetics compared to chronic and acute clones. (A) U87-CD4/CCR5
cells were spinoculated with equivalent amounts of pseudotyped virus at a temperature non-permissive for entry. Infections were synchronized by
simultaneous addition of warm medium. ENF (10 mM) was added once to wells at given times post-infection. All infections are given as a percent of
maximal infection. (B) Average T1/2 fusion values in minutes for acute (green), chronic (black), and ES (red). (C) Equivalent amounts of pseudotyped
virus were simultaneously added to Affinofile cells induced to express approximately 125,000 molecules CD4 and 1274 molecules CCR5/cell. EFV
(1 mM) was added at various times post-infection. Average T1/2 reverse transcription values in hours are shown. YU-2 and SF162 are included as
controls (B,C).
doi:10.1371/journal.ppat.1000377.g006
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mediate absolute viral suppression. Viral control could be achieved
in those individuals who are also able to mount a potent immune
response and/or are genetically predisposed to better control
HIV-1 viremia. In these individuals, viral replication and
diversification of early infection viruses required to achieve
efficient receptor utilization by env quasispecies may never be
attained. Lower fitness of other viral factors may also be
contributing to reduced replication and lower viral load. Full
understanding of the in vivo impact of lower env fitness in ES will
require further study however this data underscores the important
contribution of viral factors in elite HIV-1 suppression.
Supporting Information
Figure S1 ES and chronic envs show no difference in Env virion
incorporation.
Found at: doi:10.1371/journal.ppat.1000377.s001 (7.47 MB EPS)
Figure S2 Affinofile cells allow for the analysis of both CD4 and
CCR5.
Found at: doi:10.1371/journal.ppat.1000377.s002 (3.03 MB EPS)
Figure S3 Full surface plots for chronic progressor (CP) and elite
suppressor (ES) envelopes. (A–O) Surface plots are arranged by
patient, including Yu-2 and SF-162 control strains, indicated in
blue. CP envs are indicated in grayscale, and ES envs are indicated
in red.
Found at: doi:10.1371/journal.ppat.1000377.s003 (1.45 MB PDF)
Figure S4 Affinofile cells induced to express physiologic levels of
CD4 and CCR5 express similar surface levels as CD4
+ PBMCs.
Found at: doi:10.1371/journal.ppat.1000377.s004 (0.80 MB EPS)
Acknowledgments
Virus work at Case Western Reserve University was performed in the
biosafety level 2 and 3 facilities of the Case/UH Centers for AIDS
Research (AI25879). We would like to thank Joel N. Blankson for helpful
discussions and advice on the manuscript. Additionally, the authors wish to
thank E. M. Landaw and D. Markovic at the UCLA statistics center for
help in statistical analysis.
Author Contributions
Conceived and designed the experiments: KGL MAL. Performed the
experiments: KGL MAL. Analyzed the data: KGL MAL TC. Contributed
reagents/materials/analysis tools: JRB SJ SN BL RFS MM EJA. Wrote the
paper: KGL MAL. Provided reagents (envs), collected and cloned all of the
HIV-1 envs from elite and acute patients, involved in experimental design
and prep of the manuscript: JRB. Developed and tested the cell line and
Affinofile system, assisted in experimental design and determination of the
levels of CCR5 and CD4 in the cell system: SJ. Developed and tested the
cell line and Affinofile system, assisted in experimental design and
determination of the levels of CCR5 and CD4 in the cell system: SN.
Developed and tested the cell line and Affinofile system, assisted in
experimental design and determination of the levels of CCR5 and CD4 in
the cell system, supervised activities, helped write manuscript and guide co-
authors on the use of the Affinofile system: BL. Provided reagents (envs),
supervised activities and reviewed the re-write of the manuscript: RFS.
Identified the appropriate acutely infected patients, provided the plasma
samples for this study, and was involved in providing clinical characteristics
and in writing the manuscript: MM. Manuscript preparation, experimental
design, oversight and guidance on all of the experiments and figure
preparation: EJA.
References
1. Hubert JB, Burgard M, Dussaix E, Tamalet C, Deveau C, et al. (2000) Natural
history of serum HIV-1 RNA levels in 330 patients with a known date of
infection. The SEROCO Study Group. Aids 14: 123–131.
2. Deeks SG, Walker BD (2007) Human immunodeficiency virus controllers:
mechanisms of durable virus control in the absence of antiretroviral therapy.
Immunity 27: 406–416.
3. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, et al. (1996) Influence of
combinations of human major histocompatibility complex genes on the course of
HIV-1 infection. Nat Med 2: 405–411.
4. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al.
(2000) HLA B*5701 is highly associated with restriction of virus replication in a
subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A
97: 2709–2714.
5. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, et al. (2003) Influence
of HLA-B57 on clinical presentation and viral control during acute HIV-1
infection. Aids 17: 2581–2591.
6. Brettle RP, McNeil AJ, Burns S, Gore SM, Bird AG, et al. (1996) Progression of
HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion
intervals in 1983–1985. Aids 10: 419–430.
7. Bailey JR, Williams TM, Siliciano RF, Blankson JN (2006) Maintenance of viral
suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape
mutations. J Exp Med 203: 1357–1369.
8. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, et al. (1995)
Genomic structure of an attenuated quasi species of HIV-1 from a blood
transfusion donor and recipients. Science 270: 988–991.
9. Churchill MJ, Rhodes DI, Learmont JC, Sullivan JS, Wesselingh SL, et al.
(2006) Longitudinal analysis of human immunodeficiency virus type 1 nef/long
terminal repeat sequences in a cohort of long-term survivors infected from a
single source. J Virol 80: 1047–1052.
10. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC (1995)
Brief report: absence of intact nef sequences in a long-term survivor with
nonprogressive HIV-1 infection. N Engl J Med 332: 228–232.
11. Salvi R, Garbuglia AR, Di Caro A, Pulciani S, Montella F, et al. (1998) Grossly
defective nef gene sequences in a human immunodeficiency virus type 1-
seropositive long-term nonprogressor. J Virol 72: 3646–3657.
12. Huang Y, Zhang L, Ho DD (1995) Biological characterization of nef in long-
term survivors of human immunodeficiency virus type 1 infection. J Virol 69:
8142–8146.
13. Huang Y, Zhang L, Ho DD (1995) Characterization of nef sequences in long-
term survivors of human immunodeficiency virus type 1 infection. J Virol 69:
93–100.
14. Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, et al. (1989)
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in
the pathogenesis of acquired immunodeficiency syndrome: studies on sequential
HIV isolates. J Virol 63: 2118–2125.
15. Tersmette M, Lange JM, de Goede RE, de Wolf F, Eeftink-Schattenkerk JK, et
al. (1989) Association between biological properties of human immunodeficiency
virus variants and risk for AIDS and AIDS mortality. Lancet 1: 983–985.
16. Allen TM, O’Connor DH, Jing P, Dzuris JL, Mothe BR, et al. (2000) Tat-
specific cytotoxic T lymphocytes select for SIV escape variants during resolution
of primary viraemia. Nature 407: 386–390.
17. Allen TM, Altfeld M, Yu XG, O’Sullivan KM, Lichterfeld M, et al. (2004)
Selection, transmission, and reversion of an antigen-processing cytotoxic T-
lymphocyte escape mutation in human immunodeficiency virus type 1 infection.
J Virol 78: 7069–7078.
18. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, et al. (2005) Selective
escape from CD8+ T-cell responses represents a major driving force of human
immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals
constraints on HIV-1 evolution. J Virol 79: 13239–13249.
19. Li B, Gladden AD, Altfeld M, Kaldor JM, Cooper DA, et al. (2007) Rapid
reversion of sequence polymorphisms dominates early human immunodeficiency
virus type 1 evolution. J Virol 81: 193–201.
20. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, et al. (2007) Isolation
and characterization of replication-competent human immunodeficiency virus
type 1 from a subset of elite suppressors. J Virol 81: 2508–2518.
21. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, et al. (2008)
Genetic Characterization of Human Immunodeficiency Virus type 1 in Elite
Controllers: Lack of gross genetic defects or common amino acid changes. J Virol.
22. Joos B, Trkola A, Fischer M, Kuster H, Rusert P, et al. (2005) Low human
immunodeficiency virus envelope diversity correlates with low in vitro
replication capacity and predicts spontaneous control of plasma viremia after
treatment interruptions. J Virol 79: 9026–9037.
23. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, et al. (2006) Neutralizing
antibodies do not mediate suppression of human immunodeficiency virus type 1
in elite suppressors or selection of plasma virus variants in patients on highly
active antiretroviral therapy. J Virol 80: 4758–4770.
24. Mehandru S, Poles MA, Tenner-Racz K, Manuelli V, Jean-Pierre P, et al.
(2007) Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and
early human immunodeficiency virus type 1 infection. J Virol 81: 599–612.
25. Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ (2007) Natural variation in the
V3 crown of human immunodeficiency virus type 1 affects replicative fitness and
entry inhibitor sensitivity. J Virol 81: 8258–8269.
Lower Elite Suppressor HIV-1 env Fitness
PLoS Pathogens | www.plospathogens.org 11 April 2009 | Volume 5 | Issue 4 | e100037726. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, et al. (2000) Enhanced
levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated
using intestinal biopsy tissue. Aids 14: 1761–1765.
27. Nokta MA, Li XD, Nichols J, Mallen M, Pou A, et al. (2001) Chemokine/CD4
receptor density ratios correlate with HIV replication in lymph node and
peripheral blood of HIV-infected individuals. Aids 15: 161–169.
28. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, et al. (1997) CCR5
levels and expression pattern correlate with infectability by macrophage-tropic
HIV-1, in vitro. J Exp Med 185: 1681–1691.
29. Moore JP (1997) Coreceptors: implications for HIV pathogenesis and therapy.
Science 276: 51–52.
30. Kabat D, Kozak SL, Wehrly K, Chesebro B (1994) Differences in CD4
dependence for infectivity of laboratory-adapted and primary patient isolates of
human immunodeficiency virus type 1. J Virol 68: 2570–2577.
31. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D (1998) Effects of
CCR5 and CD4 cell surface concentrations on infections by macrophagetropic
isolates of human immunodeficiency virus type 1. J Virol 72: 2855–2864.
32. Walter BL, Wehrly K, Swanstrom R, Platt E, Kabat D, et al. (2005) Role of low
CD4 levels in the influence of human immunodeficiency virus type 1 envelope
V1 and V2 regions on entry and spread in macrophages. J Virol 79: 4828–4837.
33. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW (1999) Quantification
of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and
differentially conditioned monocyte-derived macrophages. Proc Natl Acad
Sci U S A 96: 5215–5220.
34. Meng G, Sellers MT, Mosteller-Barnum M, Rogers TS, Shaw GM, et al. (2000)
Lamina propria lymphocytes, not macrophages, express CCR5 and CXCR4
and are the likely target cell for human immunodeficiency virus type 1 in the
intestinal mucosa. J Infect Dis 182: 785–791.
35. Olsson J, Poles M, Spetz AL, Elliott J, Hultin L, et al. (2000) Human
immunodeficiency virus type 1 infection is associated with significant mucosal
inflammation characterized by increased expression of CCR5, CXCR4, and
beta-chemokines. J Infect Dis 182: 1625–1635.
36. Choudhry V, Zhang MY, Harris I, Sidorov IA, Vu B, et al. (2006) Increased
efficacy of HIV-1 neutralization by antibodies at low CCR5 surface
concentration. Biochem Biophys Res Commun 348: 1107–1115.
37. Heredia A, Gilliam B, DeVico A, Le N, Bamba D, et al. (2007) CCR5 density
levels on primary CD4 T cells impact the replication and Enfuvirtide
susceptibility of R5 HIV-1. Aids 21: 1317–1322.
38. Thomas ER, Dunfee RL, Stanton J, Bogdan D, Taylor J, et al. (2007)
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is
determined by the capacity to use low CD4 levels and overall efficiency of fusion.
Virology 360: 105–119.
39. Sagar M, Kirkegaard E, Lavreys L, Overbaugh J (2006) Diversity in HIV-1
envelope V1–V3 sequences early in infection reflects sequence diversity
throughout the HIV-1 genome but does not predict the extent of sequence
diversity during chronic infection. AIDS Res Hum Retroviruses 22: 430–437.
40. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, et al. (2002)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor
affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 99:
16249–16254.
41. Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, et al. (2004) Impact
of mutations in the coreceptor binding site on human immunodeficiency virus
type 1 fusion, infection, and entry inhibitor sensitivity. J Virol 78: 5476–5485.
42. Platt EJ, Durnin JP, Kabat D (2005) Kinetic factors control efficiencies of cell
entry, efficacies of entry inhibitors, and mechanisms of adaptation of human
immunodeficiency virus. J Virol 79: 4347–4356.
43. Safarian D, Carnec X, Tsamis F, Kajumo F, Dragic T (2006) An anti-CCR5
monoclonal antibody and small molecule CCR5 antagonists synergize by
inhibiting different stages of human immunodeficiency virus type 1 entry.
Virology 352: 477–484.
44. Bailey JR, Zhang H, Wegweiser BW, Yang HC, Herrera L, et al. (2007)
Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape.
J Infect Dis 196: 50–55.
45. Bailey JR, O’Connell K, Yang HC, Han Y, Xu J, et al. (2008) Transmission of
human immunodeficiency virus type 1 from a patient who developed AIDS to
an elite suppressor. J Virol 82: 7395–7410.
46. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, et al. (2005) The
influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS
susceptibility. Science 307: 1434–1440.
47. Cooke GS, Tosh K, Ramaley PA, Kaleebu P, Zhuang J, et al. (2006) A
polymorphism that reduces RANTES expression is associated with protection
from death in HIV-seropositive Ugandans with advanced disease. J Infect Dis
194: 666–669.
48. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, et al. (2007) CCL3L1 and
CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via
viral entry-independent mechanisms. Nat Immunol 8: 1324–1336.
49. Labrosse B, Labernardiere JL, Dam E, Trouplin V, Skrabal K, et al. (2003)
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry
inhibitors. J Virol 77: 1610–1613.
50. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, et al. (2005) Virus isolates
during acute and chronic human immunodeficiency virus type 1 infection show
distinct patterns of sensitivity to entry inhibitors. J Virol 79: 8454–8469.
51. Ketas TJ, Kuhmann SE, Palmer A, Zurita J, He W, et al. (2007) Cell surface
expression of CCR5 and other host factors influence the inhibition of HIV-1
infection of human lymphocytes by CCR5 ligands. Virology 364: 281–290.
52. Pugach P, Kuhmann SE, Taylor J, Marozsan AJ, Snyder A, et al. (2004) The
prolonged culture of human immunodeficiency virus type 1 in primary
lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology
321: 8–22.
53. Daar ES, Li XL, Moudgil T, Ho DD (1990) High concentrations of recombinant
soluble CD4 are required to neutralize primary human immunodeficiency virus
type 1 isolates. Proc Natl Acad Sci U S A 87: 6574–6578.
54. Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, et al. (2007) V3 loop
truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and
enhanced sensitivity to neutralizing antibodies. PLoS Pathog 3: e117.
doi:10.1371/journal.ppat.0030117.
Lower Elite Suppressor HIV-1 env Fitness
PLoS Pathogens | www.plospathogens.org 12 April 2009 | Volume 5 | Issue 4 | e1000377